PRQR
Bullish signalScored 2026-08-26 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
ProQR Therapeutics N.V.
- Nom
- ProQR Therapeutics N.V.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $182.0M
- Employés
- 166
- PDG
- Daniel Anton de Boer
- Site web
- https://www.proqr.com
- Marché
- ACHVALLOARCTCAPREDITIMMP
ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes two primary drug candidates in advanced clinical stages: Sepofarsen is currently in a Phase II/III clinical trial, known as the ILLUMINATE trial, targeting Leber Congenital Amaurosis 10 (LCA10). Ultevursen is also undergoing Phase II/III evaluation for the treatment of USH2A-mediated retinitis pigmentosa and Usher syndrome. Beyond its clinical programs, ProQR is actively developing its proprietary Axiomer RNA base-editing platform technology. Strategic collaborations are central to ProQR's strategy, evidenced by its licensing agreements with institutions such as Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. Furthermore, a significant license and research partnership exists with Eli Lilly and Company, focused on the discovery, advancement, and commercialization of novel medicines for genetic conditions impacting the liver and nervous system. Established in 2012, ProQR Therapeutics N.V. maintains its corporate headquarters in Leiden, the Netherlands.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
ACHAT TOTAL: 800 000 titres (~1 342 385,00 $ US)
- Insiders
- de Boer Daniel AntonFilius Bart
- Total bought
-
$1,342,385
Avg buy (VWAP, 90d window) $1.77 vs last close —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-07-31
- Last synced
-
2026-10-20 00:36:23
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-07-31 | de Boer Daniel Anton | Buy · P | 200,000 | $1.77 | $353,960 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Bullish signalScored 2026-08-26 Drivers: fundamentals. Moteurs : fondamentaux.
PRQR presents a meaningful insider cluster buy signal (800k shares, ~$1.34M) following positive Phase 1 data for AX-0810, which provides genuine near-term catalytic interest; however, the underlying financial health is…
The first sentence of the analysis written for PRQR on 2026-08-26 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Unavailable or mixed. Current ratio 3.09 · operating margin -276% — readings disagree
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 83.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Ebit Margin | -259.4% | -142.2% | -408.5% | -1641.1% | -4290.4% | |
| Ebitda Margin | -241.7% | -127.6% | -369.9% | -1571.0% | -4116.0% | |
| Operating Profit Margin | -275.9% | -161.2% | -489.1% | -1813.0% | -4285.4% | |
| Pretax Profit Margin | -265.1% | -147.9% | -427.0% | -1783.8% | -4545.5% | |
| Continuous Operations Profit Margin | -265.2% | -146.9% | -425.8% | -1786.4% | -4554.2% | |
| Net Profit Margin | -265.2% | -146.9% | -431.7% | -1792.5% | -4549.8% | |
| Bottom Line Profit Margin | -265.2% | -146.9% | -431.7% | -1792.5% | -4549.8% | |
| Current Ratio | 3.086 | 3.955 | 3.537 | 7.359 | 6.939 | |
| Quick Ratio | 3.086 | 3.955 | 3.537 | 7.359 | 6.939 | |
| Solvency Ratio | -0.508 | -0.304 | -0.240 | -0.554 | -0.533 | |
| Cash Ratio | 2.849 | 3.841 | 3.477 | 4.516 | 6.795 | |
| Price To Earnings Ratio | -4.524 | -7.527 | -5.118 | -3.797 | -7.337 | |
| Price To Earnings Growth Ratio | -0.385 | 2.634 | 0.083 | 0.729 | -2.275 | |
| Forward Price To Earnings Growth Ratio | -0.385 | 2.634 | 0.083 | 0.729 | -2.275 | |
| Price To Earnings Diluted Ratio | -4.524 | -7.527 | -5.118 | -3.797 | -7.337 | |
| Price To Earnings Diluted Growth Ratio | -0.385 | 2.634 | 0.083 | 0.729 | -2.275 | |
| Price To Book Ratio | 3.123 | 2.279 | 3.174 | 3.459 | 3.492 | |
| Price To Sales Ratio | 11.853 | 11.055 | 22.278 | 68.879 | 338.653 | |
| Price To Free Cash Flow Ratio | -3.365 | -5.527 | 7.192 | -3.577 | -17.063 | |
| Price To Operating Cash Flow Ratio | -3.430 | -5.743 | 6.735 | -3.613 | -17.380 | |
| Debt To Assets Ratio | 0.124 | 0.092 | 0.143 | 0.128 | 0.288 | |
| Debt To Equity Ratio | 0.283 | 0.175 | 0.477 | 0.328 | 0.530 | |
| Debt To Capital Ratio | 0.221 | 0.149 | 0.323 | 0.247 | 0.347 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.094 | 0.060 | 0.257 | |
| Financial Leverage Ratio | 2.284 | 1.897 | 3.331 | 2.555 | 1.841 | |
| Working Capital Turnover Ratio | 0.154 | 0.176 | 0.055 | 0.022 | 0.010 | |
| Operating Cash Flow Ratio | -1.386 | -0.903 | 0.570 | -3.058 | -0.829 | |
| Operating Cash Flow Sales Ratio | -3.455 | -1.925 | 3.308 | -19.062 | -19.485 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.019 | 1.039 | 0.936 | 1.010 | 1.019 | |
| Debt Service Coverage Ratio | -6.072 | -4.196 | -8.044 | -6.097 | -5.207 | |
| Interest Coverage Ratio | -48.655 | -28.293 | -26.483 | -12.709 | -16.802 | |
| Short Term Operating Cash Flow Coverage Ratio | -10.115 | -7.870 | 12.086 | -16.514 | -3.628 | |
| Operating Cash Flow Coverage Ratio | -3.213 | -2.263 | 0.988 | -2.922 | -0.379 | |
| Capital Expenditure Coverage Ratio | -51.756 | -25.665 | 15.717 | -96.763 | -53.744 | |
| Dividend Paid And Capex Coverage Ratio | -51.756 | -25.665 | 15.717 | -96.763 | -53.744 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -2.410 | -2.917 | -1.475 | -3.008 | -5.596 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 83.0% | ▼-17.0% | ▼-13.6% |
| Ebit Margin | -259.4% | ▼-117.2% | ▲1088.9% |
| Ebitda Margin | -241.7% | ▼-114.1% | ▲1043.5% |
| Operating Profit Margin | -275.9% | ▼-114.7% | ▲1129.0% |
| Pretax Profit Margin | -265.1% | ▼-117.2% | ▲1168.8% |
| Continuous Operations Profit Margin | -265.2% | ▼-118.3% | ▲1170.5% |
| Net Profit Margin | -265.2% | ▼-118.3% | ▲1172.0% |
| Bottom Line Profit Margin | -265.2% | ▼-118.3% | ▲1172.0% |
| Current Ratio | 3.086 | ▼-0.868 | ▼-1.889 |
| Quick Ratio | 3.086 | ▼-0.868 | ▼-1.889 |
| Solvency Ratio | -0.508 | ▼-0.204 | ▼-0.080 |
| Cash Ratio | 2.849 | ▼-0.992 | ▼-1.447 |
| Price To Earnings Ratio | -4.524 | ▲3.002 | ▲1.137 |
| Price To Earnings Growth Ratio | -0.385 | ▼-3.019 | ▼-0.542 |
| Forward Price To Earnings Growth Ratio | -0.385 | ▼-3.019 | ▼-0.542 |
| Price To Earnings Diluted Ratio | -4.524 | ▲3.002 | ▲1.137 |
| Price To Earnings Diluted Growth Ratio | -0.385 | ▼-3.019 | ▼-0.542 |
| Price To Book Ratio | 3.123 | ▲0.844 | ▲0.018 |
| Price To Sales Ratio | 11.853 | ▲0.798 | ▼-78.690 |
| Price To Free Cash Flow Ratio | -3.365 | ▲2.162 | ▲1.103 |
| Price To Operating Cash Flow Ratio | -3.430 | ▲2.312 | ▲1.256 |
| Debt To Assets Ratio | 0.124 | ▲0.032 | ▼-0.031 |
| Debt To Equity Ratio | 0.283 | ▲0.108 | ▼-0.075 |
| Debt To Capital Ratio | 0.221 | ▲0.072 | ▼-0.036 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | ▼-0.082 |
| Financial Leverage Ratio | 2.284 | ▲0.387 | ▼-0.098 |
| Working Capital Turnover Ratio | 0.154 | ▼-0.022 | ▲0.071 |
| Operating Cash Flow Ratio | -1.386 | ▼-0.482 | ▼-0.264 |
| Operating Cash Flow Sales Ratio | -3.455 | ▼-1.530 | ▲4.668 |
| Free Cash Flow Operating Cash Flow Ratio | 1.019 | ▼-0.020 | ▲0.015 |
| Debt Service Coverage Ratio | -6.072 | ▼-1.875 | ▼-0.148 |
| Interest Coverage Ratio | -48.655 | ▼-20.362 | ▼-22.067 |
| Short Term Operating Cash Flow Coverage Ratio | -10.115 | ▼-2.245 | ▼-4.907 |
| Operating Cash Flow Coverage Ratio | -3.213 | ▼-0.950 | ▼-1.655 |
| Capital Expenditure Coverage Ratio | -51.756 | ▼-26.091 | ▼-9.314 |
| Dividend Paid And Capex Coverage Ratio | -51.756 | ▼-26.091 | ▼-9.314 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -2.410 | ▲0.507 | ▲0.672 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $181.1M | $209.0M | $145.1M | $247.6M | $452.1M | |
| Enterprise value | $89.0M | $70.4M | $35.5M | $169.9M | $307.5M | |
| EV / Sales | 5.83x | 3.72x | 5.46x | 47.26x | 230.34x | |
| EV / Op. cash flow | -1.69x | -1.93x | 1.65x | -2.48x | -11.82x | |
| EV / Free cash flow | -1.65x | -1.86x | 1.76x | -2.45x | -11.61x | |
| EV / EBITDA | -2.41x | -2.92x | -1.48x | -3.01x | -5.60x | |
| Net debt / EBITDA | 2.49x | 5.75x | 4.55x | 1.38x | 2.63x | |
| Current ratio | 3.09x | 3.96x | 3.54x | 7.36x | 6.94x | |
| Income quality | 1.25x | 1.31x | -0.78x | 1.07x | 0.43x | |
| Graham net-net | $0 | $1 | $0 | $0 | $2 | |
| Tax burden | 100.0% | 99.3% | 101.1% | 100.5% | 100.1% | |
| Interest burden | 102.2% | 104.0% | 104.5% | 108.7% | 105.9% | |
| Working capital | $79.5M | $119.0M | $95.9M | $142.4M | $186.4M | |
| Invested capital | $94.3M | $133.6M | $114.5M | $159.8M | $206.2M | |
| Return on assets | -30.6% | -16.0% | -18.5% | -35.2% | -25.5% | |
| Operating ROA | -27.5% | -18.7% | -19.0% | -30.9% | -31.9% | |
| Return on tangible assets | -30.6% | -16.0% | -18.5% | -35.2% | -25.5% | |
| Return on equity | -69.9% | -30.3% | -61.5% | -90.0% | -46.9% | |
| Return on invested capital | -42.3% | -21.9% | -27.3% | -39.6% | -26.7% | |
| Return on capital employed | -44.7% | -22.8% | -27.8% | -40.6% | -27.6% | |
| Earnings yield | -22.4% | -13.3% | -19.4% | -26.0% | -13.4% | |
| Free cash flow yield | -29.7% | -18.1% | 13.9% | -28.0% | -5.9% | |
| Capex / Op. cash flow | -1.9% | -3.9% | 6.4% | -1.0% | -1.9% | |
| Capex / Depreciation | 37.7% | 51.4% | 54.6% | 28.1% | 20.8% | |
| Capex / Sales | 6.7% | 7.5% | 21.0% | 19.7% | 36.3% | |
| SG&A / Sales | 98.6% | 72.3% | 249.2% | 518.9% | 1301.0% | |
| R&D / Sales | 266.5% | 192.3% | 386.1% | 1415.3% | 3162.5% | |
| Stock comp / Sales | 26.3% | 13.5% | 47.7% | 79.8% | 465.6% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 143d | 41d | 78d | 6204d | 256d | |
| Days payables outstanding | 49d | 0d | 0d | 0d | 0d | |
| Operating cycle | 143d | 41d | 78d | 6204d | 256d | |
| Cash conversion cycle | 94d | 41d | 78d | 6204d | 256d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-10-18 ProQR Therapeutics N.V. (NASDAQ:PRQR) Stock Has Consensus Price Target of $7.60 According to Analysts ProQR Therapeutics N.V. (NASDAQ: PRQR - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the eight brokerages that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have given a buy recommendation
- 2026-10-02 ProQR Reports First Human Validation of RNA Editing Platform in Liver Disease ProQR Therapeutics NASDAQ: PRQR said its first-in-human data for AX-0810 provided dose-dependent evidence that its RNA-editing approach can modulate NTCP, a liver transporter involved in bile acid uptake. The company is developing NTCP programs for cholestatic liver diseases, initially focusing on pediatric biliary atresia.
- 2026-09-30 ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call Transcript ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call Transcript
- 2026-09-23 ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI Advisor Appointments support ProQR''s strategy to scale AI across the discovery and development of medicines using its Axiomer RNA editing platform and pipeline AX-0811, the first ProQR program identified through its AI-enabled discovered engine in clinical testing, with target engagement data expected in early January 2027 ProQR''s expanded AI strategy is directly supporting the ongoing development programs; the Company expects up to 5 clinical data readouts over the next 12 months across 4 development programs LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 23, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.
- 2026-09-09 ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026 LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing technology platform, today announced that the first participant has been dosed in the Phase 1 clinical trial of AX-0811 in healthy volunteers.
- 2026-09-02 ProQR to Participate in Upcoming Investor Conferences in September 2026 LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.
- 2026-08-21 ProQR Therapeutics: Buy For Axiomer RNA Tech Validation And Other Catalysts I initiate ProQR Therapeutics N.V. with a Buy rating, driven by strong initial human proof-of-concept for its Axiomer RNA editing platform. The company''s AX-0810 achieved 8-fold serum bile acid increases in phase 1, surpassing the 2-fold target and supporting its disease-modifying potential in biliary atresia [BA]. Upcoming catalysts include full phase 1 data for AX-0810 by end-2026, pediatric BA data from China in H1 2027, and phase 1 data for next-gen AX-0811 by end-2026.
- 2026-08-13 ProQR Announces Second Quarter 2026 Operating and Financial Results LEIDEN, Netherlands & CAMBRIDGE, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today reported its financial and operating results for the second quarter ended June 30, 2026, and provided a business update.
- 2026-08-11 Contrasting Artiva Biotherapeutics (NASDAQ:ARTV) & ProQR Therapeutics (NASDAQ:PRQR) ProQR Therapeutics (NASDAQ: PRQR - Get Free Report) and Artiva Biotherapeutics (NASDAQ: ARTV - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability. Valuation and Earnings This table compares ProQR
- 2026-08-04 ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Average Rating of “Moderate Buy” from Analysts ProQR Therapeutics N.V. (NASDAQ: PRQR - Get Free Report) has received an average rating of "Moderate Buy" from the six brokerages that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have assigned a buy recommendation to the